14.05.2019

Prof. Dr. Helga Rübsamen-Schaeff erhält den Innovationspreis 2019 des Landes Nordrhein-Westfalen
Prof. Dr. Helga Rübsamen-Schaeff erhält den Innovationspreis 2019 des Landes Nordrhein-Westfalen

more ...

04.04.2019

AiCuris to Present Clinical Data on AIC649 against Chronic Hepatitis B at the 2019 EASL meeting, the International Liver Congress
• Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups

more ...

19.03.2019

AiCuris plant sein weiteres Wachstum in Wuppertal
Unternehmen beabsichtigt Investitionen am Standort in Millionenhöhe

more ...

11.03.2019

AiCuris nominated for “Deutscher Innovationspreis 2019”
AiCuris Anti-infective Cures GmbH is one of three companies nominated for the “Deutscher Innovationspreis 2019” in the category Medium-Sized Enterprises

more ...

29.11.2018

AiCuris-Team receives German Future Prize 2018
Prof. Dr. Helga Rübsamen-Schaeff, Founding-CEO, and Dr. Holger Zimmermann, CEO of AiCuris Anti-Infective Cures GmbH, were awarded the German Future Prize 2018

more ...

28.11.2018

AiCuris-Team wins German Future Prize 2018
Prof. Dr. Helga Rübsamen-Schaeff, Founding-CEO, and Dr. Holger Zimmermann, CEO of AiCuris Anti-Infective Cures GmbH, were awarded the German Future Prize 2018

more ...

01.10.2018 14:00 Uhr

AiCuris to cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives
AiCuris and Cyclenium signing of a collaboration agreement focused on finding new pharmaceutical compounds for the treatment and prevention of bacterial and viral diseases

more ...

12.09.2018

AiCuris-Team nominated for German Future Prize 2018
•AiCuris team nominated for their project, "Protection in the Absence of the Immune System - a Life-Saving Innovation against Dangerous Viruses"

more ...

03.09.2018

AiCuris Reports Positive Phase 1 Clinical Trial Results with Immunomodulator AIC649 in Patients with Chronic Hepatitis B
Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups

more ...

25.04.2018

Approval of MSD’s PREVYMIS™ (letermovir) in Japan triggers
In March the Japanese Ministry of Health, Labor and Welfare (MLHW) granted marketing authorization to MSD for PREVYMIS™ (letermovir)

more ...